New CAS BioFinder Discovery Platform empowers drug discovery scientists to reveal insights, drive innovation, and save time

Transformative new scientific information capabilities combine an unparalleled collection of curated science data with advanced predictive models to accelerate early-stage drug discovery innovation

CAS, a division of the American Chemical Society, launched the CAS BioFinder Discovery Platform, a comprehensive life sciences offering that will reveal novel insights through unprecedented data connections. The new offering provides drug discovery scientists with the ability to explore known and predicted data, find answers to their questions quickly and reliably, and accelerate the pre-clinical drug discovery process.

The CAS BioFinder Discovery Platform taps into science content through the CAS Content Collection, which includes the world’s most comprehensive, highly structured, human-curated scientific data. In addition to connecting biological sequences, structure-activity relationship data, ADME-measurement, and toxicity to its substance collection, CAS more recently incorporated biomarker data linked to diseases and drugs. CAS leveraged Chemotargets CLARITY as the technological foundation for the CAS BioFinder predictive capabilities and analytics.

Pairing this wealth of scientific knowledge with proprietary AI-powered technology and an intuitive, visual interface, the CAS BioFinder Discovery Platform is built to serve drug discovery scientists in their research just as CAS SciFinder has served chemists and related scientists for decades. 

With the CAS BioFinder Discovery Platform, users can explore empirical data and run predictive models to understand the likely effects of novel molecules. The new platform also includes API access to bioactivity and biomarker data that scientists will be able to process using their in-house models. Over time, users will benefit from fully integrated innovation capabilities that span their spectrum of data, research, and workflow needs.

To ensure that the CAS BioFinder Discovery Platform addresses drug discovery scientists’ most salient pain points, last year CAS assembled a Life Sciences Industry Advisory Board composed of global thought leaders from commercial, academic, and government organizations who have guided the organization’s journey into life sciences. An early version of CAS BioFinder was also shared with several industry partners whose feedback has helped make the solution strong from the start.

To learn more about the CAS BioFinder Discovery Platform go here .

Read the full press release here .